Evidence map›Paper›PMID 19184567›Full record

ReviewStem cell reviews and reports2009

Pre-transplantation specification of stem cells to cardiac lineage for regeneration of cardiac tissue.

Maritza Mayorga, Amanda Finan, Marc Penn

Abstract readReview
In one paragraph

Review in Stem cell reviews and reports, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Embryonic stem cells for severe heart failure: why and how?Journal of cardiovascular translational research · 2012
    Review
  6. Challenges for heart disease stem cell therapy.Vascular health and risk management · 2012
    Review
  7. Cardiac cell therapy: the next (re)generation.Stem cell reviews and reports · 2011
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Maritza MayorgaSkirball Laboratory for Cardiovascular Cellular Therapeutics, Center for Cardiovascular Cell Therapy, Departments of Cardiovascular Medicine and Stem Cell Biology and Regenerative Medicine, Cleveland Clinic, Cleveland, OH 44195, USA.
Amanda Finan
Marc Penn

Funding

Myocardial regeneration in ischemic cardiomyopathyR01HL074400 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI PENN, MARC S · 2005 to 2009
$1.8M
NHLBI NIH HHS HL74400NHLBI NIH HHS R01 HL074400
6 · The paper itself

Abstract

Myocardial infarction (MI) is a lead cause of mortality in the Western world. Treatment of acute MI is focused on restoration of antegrade flow which inhibits further tissue loss, but does not restore function to damaged tissue. Chronic therapy for injured myocardial tissue involves medical therapy that attempts to minimize pathologic remodeling of the heart. End stage therapy for chronic heart failure (CHF) involves inotropic therapy to increase surviving cardiac myocyte function or mechanical augmentation of cardiac performance. Not until the point of heart transplantation, a limited resource at best, does therapy focus on the fundamental problem of needing to replace injured tissue with new contractile tissue. In this setting, the potential for stem cell therapy has garnered significant interest for its potential to regenerate or create new contractile cardiac tissue. While to date adult stem cell therapy in clinical trials has suggested potential benefit, there is waning belief that the approaches used to date lead to regeneration of cardiac tissue. As the literature has better defined the pathways involved in cardiac differentiation, preclinical studies have suggested that stem cell pretreatment to direct stem cell differentiation prior to stem cell transplantation may be a more efficacious strategy for inducing cardiac regeneration. Here we review the available literature on pre-transplantation conditioning of stem cells in an attempt to better understand stem cell behavior and their readiness in cell-based therapy for myocardial regeneration.

Indexed as

Cell DifferentiationCell LineageClinical Trials as TopicEmbryonic Stem CellsHeartHeart FailureHumansModels, BiologicalMuscle CellsMyocardial InfarctionMyocardiumRegenerationStem Cell TransplantationTransplantation ConditioningTreatment Outcome

Identifiers

PMID19184567
PMCPMC2758651

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.